tetano
Editor, Senior Moderator
J Virol
. 2021 Sep 22;JVI0131321.
doi: 10.1128/JVI.01313-21. Online ahead of print.
Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants
Angela Choi[SUP] 1 [/SUP], Matthew Koch[SUP] 1 [/SUP], Kai Wu[SUP] 1 [/SUP], Groves Dixon[SUP] 1 [/SUP], Judy Oestreicher[SUP] 1 [/SUP], Holly Legault[SUP] 1 [/SUP], Guillaume B E Stewart-Jones[SUP] 1 [/SUP], Tonya Colpitts[SUP] 1 [/SUP], Rolando Pajon[SUP] 1 [/SUP], Hamilton Bennett[SUP] 1 [/SUP], Andrea Carfi[SUP] 1 [/SUP], Darin K Edwards[SUP] 1 [/SUP]
Affiliations
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated as D614G). Results showed minimal, statistically non-significant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization. IMPORTANCE In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest. While the serum neutralization elicited by mRNA-1273 against most variants tested was reduced compared with the wild-type virus, they are still expected to be protective. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.
. 2021 Sep 22;JVI0131321.
doi: 10.1128/JVI.01313-21. Online ahead of print.
Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants
Angela Choi[SUP] 1 [/SUP], Matthew Koch[SUP] 1 [/SUP], Kai Wu[SUP] 1 [/SUP], Groves Dixon[SUP] 1 [/SUP], Judy Oestreicher[SUP] 1 [/SUP], Holly Legault[SUP] 1 [/SUP], Guillaume B E Stewart-Jones[SUP] 1 [/SUP], Tonya Colpitts[SUP] 1 [/SUP], Rolando Pajon[SUP] 1 [/SUP], Hamilton Bennett[SUP] 1 [/SUP], Andrea Carfi[SUP] 1 [/SUP], Darin K Edwards[SUP] 1 [/SUP]
Affiliations
- PMID: 34549975
- DOI: 10.1128/JVI.01313-21
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated as D614G). Results showed minimal, statistically non-significant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization. IMPORTANCE In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest. While the serum neutralization elicited by mRNA-1273 against most variants tested was reduced compared with the wild-type virus, they are still expected to be protective. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.